Skip to content
Investing

Pantheon Resources: An Alaska Oil Developer Seeking a Partner as Cash Runs Low

Pantheon owns the Kodiak and Ahpun fields on Alaska's North Slope but has no revenue. We look at its resources, cash, debt, the new CEO, the £5m raise and the dates to watch.

Aerial view of the drilling rig and fracking equipment at Pantheon Resources' Dubhe well pad on Alaska's snow-covered North Slope.
Photo: Pantheon Resources

Pantheon Resources owns all of two large undeveloped oil and gas fields on Alaska's North Slope. It has no production or revenue, and its next steps depend on finding a partner to pay for development and on regular share sales to fund the business in the meantime.

What Pantheon does and where

Pantheon is quoted on London's AIM market and trades in the US on the OTCQX as PTHRF. It is developing the Kodiak and Ahpun fields on State of Alaska land on the North Slope, close to existing pipeline and transport infrastructure, and holds a 100% working interest in about 259,000 acres. The company is small: its interim report puts the team at about 11 employees.

Pantheon has drilled several wells in the area. Its website timeline lists a test of the Megrez-1 well in the second quarter of 2025, and the drilling, completion and flow testing of Dubhe-1 in the second half of 2025. There has been no field activity in 2026. This year's work has been the reprocessing of seismic data and a search for a farm-out partner.

Pantheon Resources: share price, chart and news

Pantheon Resources' Dubhe well pad on Alaska's North Slope lit up at night during fracking operations, seen from the air.
Pantheon Resources' Dubhe well pad on Alaska's North Slope lit up at night during fracking operations, seen from the air. Photo: Pantheon Resources
Pantheon Resources in the three months to 12 November 2026. Daily closing prices from exchange data.
Pantheon Resources in the three months to 12 November 2026. Daily closing prices from exchange data.

The resource base

Pantheon's assets are measured as contingent resources: volumes judged potentially recoverable from known accumulations but not yet commercial. They are not reserves. The best-estimate (2C) figures come from three outside firms.

ProjectEstimated by2C oil (million barrels)2C gas (bcf)
KodiakNetherland, Sewell & Associates1,2085,396
Ahpun western topsetsCawley Gillespie & Associates282803
Ahpun Alkaid horizon (possible reserves and 2C)Lee Keeling & Associates79424

In total the company cites about 1.6 billion barrels of Alaska North Slope crude and 6.6 trillion cubic feet of associated gas. In September it said reprocessed seismic over about 238 square miles of the Kodiak up-dip area points to an increase of at least 25% in the Kodiak 2C figure. That is a preliminary management view, not prepared to industry PRMS standards; a formal estimate is still to come.

The gas is tied to the proposed Alaska LNG Project, whose pipeline route crosses Pantheon's acreage. The company has a gas sales precedent agreement with 8 Star Alaska, which is owned by the Alaska Gasline Development Corporation and Glenfarne. Pantheon says political delays have pushed back the project's timetable.

The latest numbers

Six months to 30 June 2026

  • US$9.2m loss for the period
  • US$5.5m cash at 11 September
  • 1.458bn shares in issue after 6 November

For the six months to 30 June 2026, Pantheon reported an operating loss of US$6.1 million, down from US$7.9 million a year earlier, after cutting administrative costs by 22% to US$5.3 million. The bottom-line loss of US$9.2 million compares with net income of US$2.7 million a year before, when a non-cash gain on its convertible bond lifted the result.

Cash was US$10.2 million at 30 June, down from US$24.5 million at the end of 2025, after the company settled bills for the Dubhe-1 well. By 11 September cash had fallen to US$5.5 million. Exploration and evaluation assets were carried at US$383.3 million, and the board found no sign of impairment.

Debt is a convertible bond issued in March 2025 to investors led by Sun Hung Kai & Co. After a partial redemption in shares in July 2025, US$28.5 million of principal remains. It carries a 5% coupon, matures on 24 March 2028 and has been secured by a floating charge over the group's assets since February 2026. The company says it is evaluating options for the maturity. Pantheon has also moved its financial year-end from June to December.

A new chief executive and another raise

On 1 October David Wilkins replaced Max Easley as chief executive. Wilkins has been on the board since March and has more than 40 years in the industry, including senior roles at Hilcorp Alaska and Marathon Oil. He said he was "excited to roll up my sleeves and take on the role of CEO". His pay is US$100,000 a year in cash plus 3 million shares a year for his first two years, and an initial grant of 6 million restricted stock units.

On 11 November Pantheon proposed raising about £5.0 million at 7p a share and suspended trading under an AIM Capital Access Window until the raise closes. It says the money would fund operations until about early June 2027, and chairman Michael Spencer plans to put in £750,000. At the time of writing, the result had not been announced.

Risks and what to watch

What could go wrong

  • Funding: with no revenue, the company relies on share sales or a partner. In September it estimated it would need about US$15 million to reach the end of 2027 without a farm-out
  • Dilution: each placing enlarges the share count. The shares were 23.35p at 30 June 2025 and 13.29p a year later, and the new raise is priced at 7p
  • Farm-out uncertainty: the board rejected one firm proposal and says the outcome of the talks is uncertain
  • Resource risk: contingent resources may never become reserves, and the seismic-based uplift has not been independently estimated
  • Debt: the US$28.5 million secured bond falls due in March 2028
  • Permits and infrastructure: any development needs permits, and the value of the gas depends on the delayed Alaska LNG pipeline
ItemTiming given by the company
Result of the £5.0m fundraise and return of tradingAt the close of the raise, after 11 November 2026
Formal Kodiak resource estimate using the new seismicAs soon as practicable
Farm-out agreement and a decision on an up-dip appraisal wellNo date given
Cash runway if the raise completesTo about early June 2027
Convertible bond maturity24 March 2028

Pantheon gives investors exposure to a large but unproven resource in a part of Alaska where the nearby Pikka development has started up. Turning that resource into cash flow depends on a partner, on financing and on pipeline decisions the company does not control.

Sources

Related stories

Business

Pantheon Resources Seeks £5m at 7p and Pauses Trading While Farm-Out Talks Continue

The Alaska oil developer plans a £5.0m placing and subscription at 7p, with its chairman putting in £750,000, to fund operations to about June 2027 while farm-in talks go on.

Investing

Headwater Exploration Profile: Record Output Ahead of the 18 November Tamarack Vote

Headwater Exploration pumped a record 25,555 boe/d in the third quarter with no bank debt. Here is what its holders own, what the Tamarack deal gives them and the dates that matter…

Investing

Kosmos Energy Investor Profile: Ghana Oil, GTA LNG and a Debt Clock

Kosmos Energy produces oil and gas off Ghana, Mauritania and Senegal and in the US Gulf. Its latest numbers, $2.47bn of net debt, 595.6m shares, the main risks and what to watch…

Investing

Quantum Computing Inc.: Investor Profile of the Photonics Maker With $1.3bn in the Bank

Quantum Computing Inc. sells photonic chips, packaging services and room-temperature quantum optimisation machines. It has about $1.3bn in cash and investments, but sales are small…

Investing

Aya Gold & Silver Corrects Q3 Cash Costs to $14.28 an Ounce After Silver Double Count

Aya Gold & Silver refiled its Q3 MD&A after silver in transit was deducted twice. Zgounder ounces sold rise to 1,392,478 and cash costs fall to $14.28 from $15.51. Revenue and…

Investing

FDA Rejects Summit's Lung Cancer Drug Ivonescimab Over Phase 3 Survival Miss

The FDA has rejected Summit Therapeutics' lung cancer drug ivonescimab, saying slower tumour growth in the phase 3 HARMONi trial was not enough without a clear gain in survival.

Investing

Red Cat Withdraws Its $150m to $180m 2026 Revenue Target After $11.8m Third Quarter

Red Cat Holdings has withdrawn its $150m to $180m revenue target for 2026 after third-quarter sales of $11.8m, blaming slower defence funding. Its quarterly net loss more than…

Investing

Berkshire Reveals $689m Bending Spoons Stake, Doubles Lennar and Trims Bank of America Again

Berkshire Hathaway's third-quarter 13F shows a new Bending Spoons stake worth $689m, a doubled Lennar holding and 27.5 million more Bank of America shares sold, while Apple stayed…